8-K
filed December 7, 2023, 6:59 PM ET
ticker SBFM
CIK 0001402328
other material
confidence high
sentiment neutral
materiality 0.60
Sunshine Biopharma annual meeting: directors elected, reverse split up to 1:40 approved
Sunshine Biopharma Inc.
- All five director nominees elected with >16M votes each; broker non-votes 5.04M.
- Ratification of BF Borgers as auditor approved: 20.1M for, 2.45M against.
- 2023 Equity Incentive Plan approved: 15.9M for, 1.84M against.
- Reverse stock split authorized at ratio between 1:2 and 1:40, board discretion on timing.
- Advisory vote on executive compensation approved; frequency set at every 3 years.
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Sunshine Biopharma Inc. shareholders approved Election of directors at the 2023-12-07 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2023-12-07
Exact text from the filing
At the meeting, (i) Dr. Steve N. Slilaty, Dr. Abderrazzak Merzouki, Dr. Rabi Kiderchah, Mr. David Natan, and Dr. Andrew Keller were each elected as directors of the Company to serve until the next annual meeting of stockholders or until their successors have been elected and qualified
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Sunshine Biopharma Inc. shareholders approved Ratification of the board of directors’ appointment of BF Borgers, CPA P.C. as the Company’s independent registered public accounting firm for 2023 at the 2023-12-07 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2023-12-07
Exact text from the filing
Ratification of the board of directors’ appointment of BF Borgers, CPA P.C. as the Company’s independent registered public accounting firm for 2023. FOR AGAINST ABSTAIN 20,099,526 2,452,753 418,180
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Sunshine Biopharma Inc. shareholders approved Advisory vote on frequency of future advisory votes on executive compensation at the 2023-12-07 meeting.
- Proposal
- say on pay frequency
- Outcome
- passed
- Meeting
- 2023-12-07
Exact text from the filing
Advisory vote on frequency of future advisory votes on executive compensation. 1 YEAR 2 YEARS 3 YEARS ABSTAIN BROKER NON-VOTE 1,777,275 165,011 15,063,931 923,289 5,040,953
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Sunshine Biopharma Inc. shareholders approved Approval of the Company’s 2023 Equity Incentive Plan at the 2023-12-07 meeting.
- Proposal
- equity plan
- Outcome
- passed
- Meeting
- 2023-12-07
Exact text from the filing
Approval of the Company’s 2023 Equity Incentive Plan. FOR AGAINST ABSTAIN BROKER NON-VOTE 15,915,610 1,842,630 171,266 5,040,953
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Sunshine Biopharma Inc. shareholders approved Advisory vote on executive compensation at the 2023-12-07 meeting.
- Proposal
- say on pay
- Outcome
- passed
- Meeting
- 2023-12-07
Exact text from the filing
Advisory vote on executive compensation. FOR AGAINST ABSTAIN BROKER NON-VOTE 16,196,664 1,516,235 216,607 5,040,953
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Sunshine Biopharma Inc. shareholders approved Approval of a reverse stock split of the Company’s common stock by a ratio of not less than 1-for-2 and not more than 1-for-40 at the 2023-12-07 meeting.
- Proposal
- reverse split
- Outcome
- passed
- Meeting
- 2023-12-07
Exact text from the filing
Approval of reverse stock split. FOR AGAINST ABSTAIN 20,005,507 2,657,164 307,788
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.